SGHT Sight Sciences, Inc.

BUSINESS SUMMARY

Sight Sciences develops and sells medical devices for ophthalmology and dry-eye treatment with two strategic-anchor product lines:

• OMNI Surgical System — a minimally-invasive glaucoma-surgery (MIGS) device that combines canaloplasty (opening Schlemm's canal) with trabeculotomy (cutting trabecular meshwork) in a single procedure. OMNI is positioned as a comprehensive standalone MIGS approach versus the more common stent-based MIGS devices
• TearCare — a thermal treatment system for evaporative dry-eye disease that addresses the meibomian gland dysfunction underlying many dry-eye cases

Revenue is per-procedure consumable sales for both product lines plus system placements at ophthalmology practices, ambulatory surgery centers, and hospital outpatient departments. Each new credentialed ophthalmologist represents multi-year recurring consumables-revenue stream once trained on either product.

MARKET OPPORTUNITY

The two end markets are structurally large and growing:

• MIGS market — ~5 million US adults have glaucoma; cataract-surgery patients increasingly receive MIGS as a combined procedure; standalone MIGS for non-cataract patients is the growth-tier where OMNI competes
• Dry-eye market — ~30 million US adults experience dry-eye symptoms; meibomian gland dysfunction is the primary cause in evaporative dry-eye patients; TearCare's thermal-treatment approach is positioned against in-office IPL alternatives and prescription-medication-only treatment

Competitive landscape:

• MIGS: iStent (Glaukos), Hydrus (Alcon), Xen (Allergan/AbbVie) — all established alternatives
• Dry-eye: LipiFlow (Alcon-acquired), various IPL devices, prescription medications

Revenue growth has been moderate with adoption-cycle dynamics on both product lines.

REVENUE QUALITY

• Gross margin — high for medical-device consumables economics
• Operating margin — TTM negative; ongoing commercial-team capex on both product lines dominates
• Revenue ~$80M+ TTM
• P/S ~3 — reflects medical-device-launch optimism plus dual-product portfolio premium

The right framework: trained-physician count plus per-physician procedure-volume for OMNI; TearCare adoption-rate plus per-patient retreatment cadence. Aggregate revenue blends two distinct adoption curves.

COMPETITIVE ADVANTAGE

The defensible asset combines IP-protected device technology with multi-year ophthalmologist relationships:

• OMNI's combined canaloplasty-trabeculotomy approach has clinical-evidence supporting reduced reoperation rates versus single-mechanism MIGS alternatives
• TearCare's thermal-treatment-with-real-time-temperature-monitoring differentiates against alternative dry-eye approaches
• Dual-product cross-sell within ophthalmology practices that treat both glaucoma and dry-eye patients

The vulnerability: at the MIGS-tier, Glaukos (iStent) is much larger with broader sales-team scale; at the dry-eye-tier, Alcon's LipiFlow has more established market presence.

GROWTH THESIS

Three structural drivers support multi-year growth: continued OMNI adoption in standalone-MIGS use cases, TearCare adoption acceleration as dry-eye treatment patterns shift toward in-office procedural approaches, and dual-product portfolio leverage at ophthalmology practices.

International expansion provides additional growth optionality but is smaller near-term contribution.

KEY RISKS

Three risks dominate. First, competitive pressure at both product lines from larger established competitors (Glaukos at MIGS, Alcon at dry-eye). Second, reimbursement-rate compression for either product category — CMS rate-setting decisions affect per-procedure economics. Third, ophthalmologist-adoption-cycle pace — if either product fails to gain meaningful additional adoption, the launch-trajectory compresses.

VERDICT

Sight Sciences is a dual-product ophthalmology medical-device launch with credible clinical-differentiation evidence on both fronts. The 60.0/100 score captures launch-execution-uncertainty more than structural quality.

For investors who want ophthalmology medical-device-launch exposure with dual-product diversification, SGHT is one of few liquid public-market vehicles. For investors needing scale or wanting single-product MIGS or dry-eye exposure, Glaukos or Alcon are the larger alternatives.